The Compound Management and Screening Center (COMAS) at the Max Planck Institute of Molecular Physiology bridges cutting-edge science and medical research. Our mission is to translate the Max Planck Society’s scientific expertise into innovative screening solutions for biomedical research and drug development.

We offer:

• A state-of-the-art infrastructure for managing chemical compound libraries
• High-throughput biochemical and cellular screening (HTS) to identify bioactive small molecule modulators
• A unique compound collection, enriched with a variety of compounds, including natural product-derived structures, kinase inhibitors and FDA approved drugs
• A central database linking each compound to comprehensive biological data

Our collaborative screening pipelines are designed to faithfully replicate biological systems, helping you identify and prioritize chemical modulators with therapeutic potential. (>> ACCESS)

Interested in the identification of chemical modulators for your biological system? Please contact Sonja Sievers